Belviq is a trade name of weight loss tablets, containing 10mg of active ingredient Lorcaserin Hydrochloride. This active ingredient is included in a pharmacological group of serotonin 2C receptor agonists.

Arena Pharmaceutical is the developer of the active ingredient Lorcaserin and the manufacturer of Belviq tablets. Arena biopharmaceutical company produces Belviq (Lorcaserin) tablets in Switzerland.

A japan company Eisai is an exclusive distributer of Belviq tablets to most countries of the world. Belviq tablets are supplied to some Pacific-Asian countries by Ildong and CY Biotech.

The USA is the first country, where Belviq tablets became available for retail sale in 2013. It is expected that in 2014, Belviq tablets will be on sale in Canada, Mexico, Canada and EU (including the UK).

Belviq weight loss drug has been developed for over 10 years. During this period, Arena Pharmaceuticals conducted 18 clinical studies of Belviq. After studying the results of clinical trials, the Food and Drug Administration (FDA) confirmed that benefits of Belviq weight loss tablets surpass their potential risks.

The FDA approved Belviq in June 2012. Sale of Belviq tablets in the USA was started in June 2013. Approval requests for selling Belviq in Canada, Mexico and EU were made in 2013. The approval request for selling Belviq in Brazil was made in 2014.

In the USA, Belviq tablets are prescribed for obesity treatment to obese patients with BMI 30 and higher. In addition, Belviq tablets can be prescribed to overweight patients (BMI 27 to 29.9) with cardiometabolic and other risk factors.

Belviq tablets must never be prescribed to children under 18 years old, pregnant and breastfeeding women, patients who are hypersensitive to Lorcaserin and some other groups of patients.

Belviq tablets may cause the CNS side effects (nausea, headache or fatigue) and gastrointestinal side effects (nausea, constipation or dry mouth). In diabetic patients, Belviq tablets may cause cough, back pain and hypoglycemia.

Patients, who took part in clinical trials, did not take Belviq with alcohol. Because Belviq and alcohol interaction has not been studied, you should refrain from alcoholic beverages throughout medical anti-obesity therapy.

During clinical trials, the doses 1 mg to 40 mg of Belviq have been studied. The results of these trials have shown that Belviq 20mg is a maximal and safe daily dose (one Belviq 10mg tablet, two times a day).

Insomnia is one of the side effects of Belviq tablets. When respecting the dose regimen of Belviq, insomnia occurs rarely. Most often, insomnia occurs in diabetic patients.

Children and teenagers under 18 years old have not been involved in clinical studies of Belviq. Therefore, some alternative weight loss medications should be used for the treatment of obesity in children and teens.

If you want to use Belviq 10mg tablets to fight obesity, you should undergo a comprehensive medical examination. You can get the prescription for Belviq only if this weight loss medication does not create any potential risk for your health.

In the USA, the first generic drugs will appear no sooner than in 2026. In other developed countries of the world, Belviq generic drugs can go on sale in 2023. Belviq generic drugs, produced in India can appear on sale in 2014. The only licensed distributors of weight loss tablets, containing Lorcaserin in 2014 are Eisai, CY Biotech and Ildong.

Some U.S. pharmacies offer to buy Belviq tablets online. The cost of Belviq at online pharmacies is lower than the price of Belviq tablets at retail pharmacy networks. Therefore, buying Belviq online, you can offset your costs for obesity treatment.